Related references
Note: Only part of the references are listed.Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics
David Gurwitz
DRUG DEVELOPMENT RESEARCH (2020)
Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
Yushun Wan et al.
JOURNAL OF VIROLOGY (2020)
COVID-19 and the cardiovascular system
Ying-Ying Zheng et al.
NATURE REVIEWS CARDIOLOGY (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Daniel Batlle et al.
CLINICAL SCIENCE (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu et al.
JAMA INTERNAL MEDICINE (2020)
Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker
Masato Furuhashi et al.
AMERICAN JOURNAL OF HYPERTENSION (2015)
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Y Imai et al.
NATURE (2005)
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
CM Ferrario et al.
CIRCULATION (2005)
Share Paper
